ATE251642T1 - Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides - Google Patents

Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides

Info

Publication number: ATE251642T1
Authority: AT; Austria
Prior art keywords: glucagon; biologically active; active fragments; insulinotropic peptides; polypeptides
Prior art date: 1994-08-30

Application number

AT95305963T

Other languages

English (en)

Inventor

William Terry Johnson

Fatima Emitsela Yakubu-Madus

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-30

Filing date

1995-08-25

Publication date

2003-10-15

1995-08-25 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2003-10-15 Application granted granted Critical

2003-10-15 Publication of ATE251642T1 publication Critical patent/ATE251642T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
230000002473 insulinotropic effect Effects 0.000 title abstract 2
239000012634 fragment Substances 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
102400000321 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
230000004190 glucose uptake Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

AT95305963T 1994-08-30 1995-08-25 Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides ATE251642T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/297,731 US5574008A (en)	1994-08-30	1994-08-30	Biologically active fragments of glucagon-like insulinotropic peptide

Publications (1)

Publication Number	Publication Date
ATE251642T1 true ATE251642T1 (de)	2003-10-15

Family

ID=23147523

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95305963T ATE251642T1 (de)	1994-08-30	1995-08-25	Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides

Country Status (10)

Country	Link
US (1)	US5574008A (de)
EP (1)	EP0699686B1 (de)
AT (1)	ATE251642T1 (de)
AU (1)	AU3372595A (de)
DE (1)	DE69531889T2 (de)
DK (1)	DK0699686T3 (de)
ES (1)	ES2208666T3 (de)
PT (1)	PT699686E (de)
SI (1)	SI0699686T1 (de)
WO (1)	WO1996006628A1 (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
US5614492A (en) *	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en)	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
WO1998005351A1 (en)	1996-08-08	1998-02-12	Amylin Pharmaceuticals, Inc.	Methods for regulating gastrointestinal motility
EP0996459B1 (de)	1997-01-07	2005-09-21	Amylin Pharmaceuticals, Inc.	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US5846937A (en) *	1997-03-03	1998-12-08	1149336 Ontario Inc.	Method of using exendin and GLP-1 to affect the central nervous system
US7157555B1 (en) *	1997-08-08	2007-01-02	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
WO1999025727A2 (en)	1997-11-14	1999-05-27	Amylin Pharmaceuticals, Inc.	Novel exendin agonist compounds
US7223725B1 (en)	1997-11-14	2007-05-29	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
US6703359B1 (en) *	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
KR100637433B1 (ko) *	2004-05-24	2006-10-20	삼성에스디아이 주식회사	발광 표시 장치
AU2610599A (en) *	1998-02-27	1999-09-15	Novo Nordisk A/S	N-terminally truncated glp-1 derivatives
AU5027299A (en)	1998-07-31	2000-02-28	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes
US6720407B1 (en) *	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
US7259136B2 (en) *	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
DE69922043T2 (de)	1998-12-07	2005-11-24	Société de Conseils de Recherches et d'Applications Scientifiques S.A.S.	Glp-1 analoge
US7919109B2 (en)	1999-02-08	2011-04-05	Intarcia Therapeutics, Inc.	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en)	1999-02-08	2007-08-21	Alza Corporation	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
WO2000055203A1 (en)	1999-03-15	2000-09-21	Novo Nordisk A/S	Ion exchange chromatographic separation of glp-1 and related peptides
US6605648B1 (en) *	1999-04-06	2003-08-12	Phillips Plastics Corporation	Sinterable structures and method
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
US20090175821A1 (en) *	1999-05-17	2009-07-09	Bridon Dominique P	Modified therapeutic peptides with extended half-lives in vivo
CA2363712C (en)	1999-05-17	2011-05-10	Conjuchem Inc.	Long lasting insulinotropic peptides
ES2569916T3 (es)	1999-06-29	2016-05-13	Mannkind Corporation	Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
US6844321B2 (en)	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
JP2003525908A (ja)	2000-03-08	2003-09-02	ノボノルディスクアクティーゼルスカブ	血清脂質の低下
EP2206720A1 (de)	2000-04-12	2010-07-14	Human Genome Sciences, Inc.	Albuminfusionsproteine
CA2430934C (en)	2000-12-01	2011-06-21	Takeda Chemical Industries, Ltd.	A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
WO2002085406A1 (en) *	2001-04-24	2002-10-31	Restoragen, Inc.	Methods and compositions for treating conditions associated with insulin resistance
EP1411968B1 (de) *	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp 1 exendin 4 peptidanaloga und deren verwendungen
US6642003B2 (en)	2001-08-02	2003-11-04	Cedars-Sinai Medical Center	Human glucose-dependent insulin-secreting cell line
AU2002364587A1 (en) *	2001-12-21	2003-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2261250B1 (de)	2001-12-21	2015-07-01	Human Genome Sciences, Inc.	GCSF-Albumin Fusionsproteine
US7141240B2 (en) *	2002-03-12	2006-11-28	Cedars-Sinai Medical Center	Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
US6923175B2 (en)	2002-03-20	2005-08-02	Mannkind Corporation	Inhalation apparatus
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7790681B2 (en) *	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) *	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
EP1617888B1 (de)	2003-04-23	2019-06-12	Valeritas, Inc.	Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten
EP1631308B1 (de) *	2003-05-30	2013-07-31	Amylin Pharmaceuticals, LLC	Neue verfahren und zusammensetzungen für die verbesserte transmukosale abgabe von peptiden und proteinen
EP1664108B1 (de)	2003-08-21	2009-10-14	Novo Nordisk A/S	Trennung von polypeptiden mit einer racemisierten aminosäure
US20070275877A1 (en) *	2003-08-29	2007-11-29	Amylin Pharmaceuticals, Inc.	Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
TR201906789T4 (tr)	2003-11-20	2019-05-21	Novo Nordisk As	Üretim ve enjeksiyon cihazlarında kullanım için en uygun olan propilen glikol ihtiva eden peptit formülasyonları.
ATE498404T1 (de)	2003-12-09	2011-03-15	Novo Nordisk As	Regulierung der nahrungspräferenz mit glp-1- agonisten
CA2550217A1 (en) *	2003-12-12	2005-07-07	Michael A. Brownlee	Glp-1 (9-36) methods and compositions
US20080194483A1 (en) *	2003-12-12	2008-08-14	Brownlee Michael A	GLP-1 (9-36) methods and compositions
US7521527B2 (en)	2003-12-16	2009-04-21	Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.	GLP-1 pharmaceutical compositions
EP1711523B1 (de)	2003-12-16	2012-10-10	Ipsen Pharma	Glp-1-analoga
ES2567634T3 (es) *	2004-02-09	2016-04-25	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina
DK2100904T3 (da)	2004-04-23	2010-11-08	Conjuchem Biotechnologies Inc	Fast fase til anvendelse i en fremgangsmåde til rensning af albuminkonjugater
US20090069226A1 (en) *	2004-05-28	2009-03-12	Amylin Pharmaceuticals, Inc.	Transmucosal delivery of peptides and proteins
JP2008501765A (ja)	2004-06-11	2008-01-24	ノボ　ノルディスク　アクティーゼルスカブ	Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
WO2006014425A1 (en)	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
ATE486064T1 (de)	2004-08-20	2010-11-15	Mannkind Corp	Katalyse der diketopiperazinsynthese
KR20130066695A (ko)	2004-08-23	2013-06-20	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
DE102004043153B4 (de) *	2004-09-03	2013-11-21	Philipps-Universität Marburg	Erfindung betreffend GLP-1 und Exendin
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
MX373000B (es)	2005-09-14	2020-05-21	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8039432B2 (en)	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
WO2007064757A1 (en) *	2005-11-29	2007-06-07	University Of Florida Research Foundation, Inc.	Anti-thymocyte globulin to prevent or delay the onset or the progression on type 1 diabetes
JP5096363B2 (ja)	2005-12-16	2012-12-12	ネクターセラピューティックス	Ｇｌｐ−１のポリマ複合体
CN101379075B (zh) *	2006-02-08	2013-05-15	隆萨股份公司	类胰高血糖素肽的合成
EP1986679B1 (de)	2006-02-22	2017-10-25	MannKind Corporation	Verfahren zur verbesserung der pharmazeutischen eigenschaften von mikropartikeln mit diketopiperazin und einem wirkstoff
CN103239773B (zh)	2006-03-30	2015-08-26	瓦莱里塔斯公司	多筒式流体递送器械
MX2008014870A (es)	2006-05-30	2009-02-12	Intarcia Therapeutics Inc	Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (de)	2006-08-09	2012-11-14	Intarcia Therapeutics, Inc.	Osmotische freisetzungssysteme und kolbenanordnungen
HRP20130259T1 (hr)	2007-04-23	2013-04-30	Intarcia Therapeutics, Inc.	Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
EP2578677A1 (de)	2007-08-09	2013-04-10	Genzyme Corporation	Verfahren zur Behandlung von Autoimmunerkrankungen mit mesenchymalen Stammzellen
US8758761B2 (en) *	2007-09-30	2014-06-24	University Of Florida Research Foundation, Inc.	Combination therapies for treating type 1 diabetes
EP2211842B1 (de) *	2007-10-24	2015-08-12	MannKind Corporation	Eine inhalierbare, trockenpulver-formulierung, enthaltend glp-1 zur verwendung in der behandlung von hyperglykämie und diabetes durch pulmonale verabreichung
JP5813323B2 (ja) *	2007-10-24	2015-11-17	マンカインドコーポレイション	活性薬剤の送達方法
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
EP2231191A2 (de) *	2007-12-11	2010-09-29	ConjuChem Biotechnologies Inc.	Formulierung von insulinotropen peptid-konjugaten
DK2240155T3 (da)	2008-02-13	2012-09-17	Intarcia Therapeutics Inc	Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
CN101827626B (zh)	2008-06-13	2015-03-18	曼金德公司	干粉吸入器和用于药物输送的系统
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2421385T3 (es)	2008-06-20	2013-09-02	Mannkind Corp	Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
WO2010054326A2 (en)	2008-11-07	2010-05-14	The General Hospital Corporation	C-terminal fragments of glucagon-like peptide-1 (glp-1)
JP5756407B2 (ja)	2008-12-08	2015-07-29	ノヴォノルディスクアー／エス	ポリペプチドの向流精製
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko)	2009-06-12	2023-10-04	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
SMT201700583T1 (it)	2009-09-28	2018-01-11	Intarcia Therapeutics Inc	Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
BR112012012945A2 (pt)	2009-11-25	2020-12-29	Arisgen Sa	Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
US9168288B2 (en)	2010-04-09	2015-10-27	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
CA2797033C (en)	2010-04-22	2021-10-19	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
CN102985125A (zh)	2010-06-21	2013-03-20	曼金德公司	干粉药物输送系统和方法
RU2013103763A (ru)	2010-07-02	2014-08-10	Ангиохем Инк.	Короткие и содержащие d-аминокислоты полипептиды для терапевтических конъюгатов и их применения
WO2012054822A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Glp-1 polymer conjugates having a releasable linkage
US9040481B2 (en)	2010-11-02	2015-05-26	The General Hospital Corporation	Methods for treating steatotic disease
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
SG194034A1 (en)	2011-04-01	2013-11-29	Mannkind Corp	Blister package for pharmaceutical cartridges
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
WO2013006692A2 (en)	2011-07-06	2013-01-10	The General Hospital Corporation	Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
MX2014004983A (es)	2011-10-24	2014-09-22	Mannkid Corp	Metodos y composiciones para tratar dolor.
TW201402611A (zh)	2012-06-21	2014-01-16	Univ Indiana Res & Tech Corp	具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物
EP2873422A4 (de)	2012-07-10	2015-12-30	Takeda Pharmaceutical	Pharmazeutische zubereitung zur injektion
KR102264177B1 (ko)	2012-07-12	2021-06-11	맨카인드 코포레이션	건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
US9789164B2 (en)	2013-03-15	2017-10-17	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
EP3587404B1 (de)	2013-03-15	2022-07-13	MannKind Corporation	Mikrokristalline diketopiperazinzusammensetzungen, verfahren zur herstellung und deren verwendung
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (de)	2013-08-05	2020-10-07	MannKind Corporation	Insufflationsvorrichtung
WO2015095684A1 (en)	2013-12-20	2015-06-25	Indiana University Research And Technology Corporation	Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
CN104267194B (zh) *	2014-09-23	2016-01-13	上海市东方医院	人胰高血糖素样肽-1、抗体及其试剂盒
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
US10925639B2 (en)	2015-06-03	2021-02-23	Intarcia Therapeutics, Inc.	Implant placement and removal systems
RU2760007C2 (ru)	2016-05-16	2021-11-22	Интарсия Терапьютикс, Инк.	Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
CN110225762A (zh)	2017-01-03	2019-09-10	因塔西亚制药公司	包括glp-1受体激动剂的连续施用和药物的共同施用的方法
HRP20240485T1 (hr)	2017-08-24	2024-07-05	Novo Nordisk A/S	Pripravci glp-1 i njihova upotreba
AR116632A1 (es)	2018-10-11	2021-05-26	Intarcia Therapeutics Inc	Polipéptidos análogos de la amilina humana y sus métodos de uso
PE20230819A1 (es)	2020-02-18	2023-05-19	Novo Nordisk As	Composiciones y usos de glp-1
US20240300999A1 (en) *	2021-06-29	2024-09-12	Thomas A. Gill	Peptides for regulating glucose

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en) *	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
US4710473A (en)	1983-08-10	1987-12-01	Amgen, Inc.	DNA plasmids
US5120712A (en) *	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
ATE110083T1 (de) *	1986-05-05	1994-09-15	Gen Hospital Corp	Insulinotropes hormon.
US5118666A (en) *	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
US4923967A (en)	1988-09-26	1990-05-08	Eli Lilly And Company	Purification and refolding of recombinant proteins
JPH04504246A (ja) *	1989-03-20	1992-07-30	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン刺激ホルモン
ATE164852T1 (de) *	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
SK155694A3 (en) *	1992-06-15	1995-05-10	Pfizer	Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
NZ250844A (en) *	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use

1994
- 1994-08-30 US US08/297,731 patent/US5574008A/en not_active Expired - Fee Related
1995
- 1995-08-25 SI SI9530684T patent/SI0699686T1/xx unknown
- 1995-08-25 DK DK95305963T patent/DK0699686T3/da active
- 1995-08-25 EP EP95305963A patent/EP0699686B1/de not_active Expired - Lifetime
- 1995-08-25 AT AT95305963T patent/ATE251642T1/de not_active IP Right Cessation
- 1995-08-25 PT PT95305963T patent/PT699686E/pt unknown
- 1995-08-25 DE DE69531889T patent/DE69531889T2/de not_active Expired - Fee Related
- 1995-08-25 ES ES95305963T patent/ES2208666T3/es not_active Expired - Lifetime
- 1995-08-25 WO PCT/US1995/010793 patent/WO1996006628A1/en not_active Ceased
- 1995-08-25 AU AU33725/95A patent/AU3372595A/en not_active Abandoned

Also Published As

Publication number	Publication date
EP0699686A3 (de)	1996-10-16
AU3372595A (en)	1996-03-22
ES2208666T3 (es)	2004-06-16
DE69531889T2 (de)	2004-07-22
EP0699686B1 (de)	2003-10-08
EP0699686A2 (de)	1996-03-06
US5574008A (en)	1996-11-12
DK0699686T3 (da)	2004-02-16
SI0699686T1 (en)	2004-02-29
WO1996006628A1 (en)	1996-03-07
DE69531889D1 (de)	2003-11-13
PT699686E (pt)	2004-02-27

Legal Events

Date

Code

Title

Description

2004-07-15

UEP

Publication of translation of european patent specification

Ref document number: 0699686

Country of ref document: EP

2007-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE251642T1 (de)	2003-10-15	Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides
ATE193541T1 (de)	2000-06-15	Insulinotropes hormon
ATE285473T1 (de)	2005-01-15	Glucagon-ähnliche insulinotrope peptid-analoge, zusammensetzungen und verwendungsverfahren
ATE164852T1 (de)	1998-04-15	Glp-1-analoga verwendbar in der diabetesbehandlung
MXPA04003553A (es)	2004-07-22	Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
ATE480259T1 (de)	2010-09-15	Intranasale verabreichung von glucose- regulierenden peptiden
BR9710452A (pt)	1999-08-17	Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
NZ517012A (en)	2003-02-28	Peptides that lower blood glucose levels
MY121291A (en)	2006-01-28	Fracture healing using pthrp analogs
HUT68525A (en)	1995-06-28	Pharmaceutical compositions of prolonged delivery, containing peptides
ATE536881T1 (de)	2011-12-15	Glp-1, exendin-4, peptid-analoga und verwendungen davon
WO2004094461A3 (en)	2005-09-15	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
BG103362A (en)	2000-05-31	Insulin c-peptides
MX9203175A (es)	1993-04-01	Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
ECSP951557A (es)	1997-07-28	Analogos composiciones y procedimientos de uso de peptidos insulinotropicos similares al glucagon
ECSP993116A (es)	1999-11-29	Procedimiento para administrar peptidos insulinotropicos